Literature DB >> 10338525

Increased antimycobacterial immunity in interleukin-10-deficient mice.

P J Murray1, R A Young.   

Abstract

Macrophage effector functions are essential for clearing mycobacterial infections. Interleukin 10 (IL-10) negatively regulates macrophages and could be a factor inhibiting effective antimycobacterial immunity. We previously showed that transgenic mice which produce excess IL-10 from T cells are susceptible to infection, even though these mice continue to produce gamma interferon (IFN-gamma) at levels similar to those in controls. Here, we extend our genetic analysis of the functions of IL-10 in antimycobacterial immunity by testing the hypothesis that IL-10-deficient (IL-10(-/-)) mice should be more resistant to mycobacteria than control mice. Mycobacterium bovis bacillus Calmette-Guérin-infected IL-10(-/-) mice had significantly lower bacterial burdens than control mice early in the infection. Contrary to expectations, however, IL-10(-/-) mice did not have increased levels of IFN-gamma, either from T cells or in the plasma, suggesting that other mechanisms are responsible for the increased resistance. However, macrophages from IL-10(-/-) mice produced increased levels of inflammatory cytokines, including IFN-gamma, as well as nitric oxide and prostaglandins, which could account for increased antimycobacterial immunity. Our genetic analysis revealed that IL-10 is an inhibitor of early mycobacterial clearance. The data also suggest that IL-10 negatively regulates numerous macrophage functions as well as playing a role in down-regulating the general inflammatory response, especially in conditions where an infection must be controlled through macrophage activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10338525      PMCID: PMC96626          DOI: 10.1128/IAI.67.6.3087-3095.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  Opposing effects of interferon-gamma on iNOS and interleukin-10 expression in lipopolysaccharide- and mycobacterial lipoarabinomannan-stimulated macrophages.

Authors:  T I Roach; C H Barton; D Chatterjee; F Y Liew; J M Blackwell
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

2.  Functional regions of the mouse interleukin-10 receptor cytoplasmic domain.

Authors:  A S Ho; S H Wei; A L Mui; A Miyajima; K W Moore
Journal:  Mol Cell Biol       Date:  1995-09       Impact factor: 4.272

3.  Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10.

Authors:  C Bogdan; J Paik; Y Vodovotz; C Nathan
Journal:  J Biol Chem       Date:  1992-11-15       Impact factor: 5.157

Review 4.  Interleukin-10.

Authors:  K W Moore; A O'Garra; R de Waal Malefyt; P Vieira; T R Mosmann
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

5.  Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice.

Authors:  L E Bermudez; J Champsi
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

6.  Inhibition by interleukin-10 of inducible cyclooxygenase expression in lipopolysaccharide-stimulated monocytes: its underlying mechanism in comparison with interleukin-4.

Authors:  H Niiro; T Otsuka; T Tanabe; S Hara; S Kuga; Y Nemoto; Y Tanaka; H Nakashima; S Kitajima; M Abe
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

7.  Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells.

Authors:  D J Stuehr; C F Nathan
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

8.  Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages.

Authors:  J Chan; Y Xing; R S Magliozzo; B R Bloom
Journal:  J Exp Med       Date:  1992-04-01       Impact factor: 14.307

9.  Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta.

Authors:  Y Vodovotz; C Bogdan; J Paik; Q W Xie; C Nathan
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

10.  Macrophage deactivation by interleukin 10.

Authors:  C Bogdan; Y Vodovotz; C Nathan
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more
  59 in total

Review 1.  Model for immune responses to Mycobacterium avium subspecies paratuberculosis in cattle.

Authors:  Paul M Coussens
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

2.  Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity.

Authors:  Tanja Schreiber; Stefan Ehlers; Lisa Heitmann; Alexandra Rausch; Jörg Mages; Peter J Murray; Roland Lang; Christoph Hölscher
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

3.  Autocrine IL-10 Signaling Promotes Dendritic Cell Type-2 Activation and Persistence of Murine Cryptococcal Lung Infection.

Authors:  Seagal Teitz-Tennenbaum; Steven P Viglianti; Jonathan A Roussey; Stuart M Levitz; Michal A Olszewski; John J Osterholzer
Journal:  J Immunol       Date:  2018-08-10       Impact factor: 5.422

4.  Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria.

Authors:  Frank A W Verreck; Tjitske de Boer; Dennis M L Langenberg; Marieke A Hoeve; Matthijs Kramer; Elena Vaisberg; Robert Kastelein; Arend Kolk; René de Waal-Malefyt; Tom H M Ottenhoff
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-19       Impact factor: 11.205

5.  CD36 deficiency attenuates experimental mycobacterial infection.

Authors:  Michael Hawkes; Xiaoming Li; Maryanne Crockett; Angelina Diassiti; Constance Finney; Gundula Min-Oo; W Conrad Liles; Jun Liu; Kevin C Kain
Journal:  BMC Infect Dis       Date:  2010-10-15       Impact factor: 3.090

6.  Human IL10 gene repression by Rev-erbα ameliorates Mycobacterium tuberculosis clearance.

Authors:  Vemika Chandra; Sahil Mahajan; Ankita Saini; Hedwin K Dkhar; Ravikanth Nanduri; Ella B Raj; Ashwani Kumar; Pawan Gupta
Journal:  J Biol Chem       Date:  2013-02-28       Impact factor: 5.157

7.  Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis.

Authors:  M Glória Bonecini-Almeida; John L Ho; Neio Boéchat; Richard C Huard; Sadhana Chitale; Howard Doo; Jiayuan Geng; Lorena Rego; Luiz Claudio Oliveira Lazzarini; Afrânio L Kritski; Warren D Johnson; Timothy A McCaffrey; José R Lapa e Silva
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

8.  Immune regulatory effect of pHSP65 DNA therapy in pulmonary tuberculosis: activation of CD8+ cells, interferon-gamma recovery and reduction of lung injury.

Authors:  V L D Bonato; E D C Gonçalves; E G Soares; R R Santos Júnior; A Sartori; A A M Coelho-Castelo; C L Silva
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

9.  IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge.

Authors:  K Kai McKinstry; Tara M Strutt; Amanda Buck; Jonathan D Curtis; John P Dibble; Gail Huston; Michael Tighe; Hiromasa Hamada; Stewart Sell; Richard W Dutton; Susan L Swain
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

10.  CCL2 responses to Mycobacterium tuberculosis are associated with disease severity in tuberculosis.

Authors:  Zahra Hasan; Jacqueline M Cliff; Hazel M Dockrell; Bushra Jamil; Muhammad Irfan; Mussarat Ashraf; Rabia Hussain
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.